This article reviews the physiological mechanisms of heart rate control via the funny current and discusses NICE guidance for ivabradine in heart failure.
In the normal heart the sinus node determines the heart rate.1 Sino-atrial myocytes are characterised by a poorly developed contractile system and self-generating repetitive action potentials, a feature not found in the myocytes of cardiac muscle. At the end of the action potential, depolarisation of the membrane voltage continues, during phase four, until this triggers another action potential. While sino-atrial myocytes are heavily innervated by both sympathetic and vagal nerves, the spontaneous activity is independent of innervation. The mechanisms controlling, or modifying, these spontaneous diastolic depolarisations are central to interventions that might be employed to modify heart rate. Early thinking attributed pacemaker activity to the decay of an outward K+ current, but in the late 1970s Brown et al identified, to their surprise, a new likely inward current accordingly described as a ‘funny current or I f ’.2 Although many questions remain unanswered,3 I f is now recognised as an Na/K inward current activated by hyperpolarisation and modulated by the autonomic nervous system. Adrenaline induced rate acceleration in sino-atrial myocytes is almost entirely due to shortening of the diastolic duration with minimal effect on action potential shape and duration2 in contrast to adrenalin-mediated influences on cardiac action potentials elsewhere. Vagal influences are similarly associated with slowing of phase four of the sino-atrial myocytes rather than influencing the morphology elsewhere. There appears to be upregulation of the I f channel in cardiac hypertrophy and heart failure (HF).4 ,5 While there is extensive evidence that a slower heart rate is associated with better outcomes, be that as a marker of overall fitness in the general population,6 ,7 in people with a range of cardiovascular conditions,8–10 in HF specifically,11 ,12 or to the diverse therapeutic effects of β-blockers in HF,13 , …
No takes yet. Share an insight, caveat, or question.
Suzanna M.C. Hardman (2013) conducted a review in Heart failure. Ivabradine was evaluated. Heart rate reduction via modulation of the funny current (If) is associated with better outcomes in heart failure, providing the mechanistic rationale for ivabradine therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: